View More View Less
  • 1 Dél-Pesti Centrumkórház – Országos Hematológiai és Infektológiai Intézet, Budapest, Albert Flórián u 5–7., 1097
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

A humán cytomegalovirusinfekció a leggyakoribb emberi vírusfertőzések közé tartozik. Ép immunrendszerű személyekben kezelést rendszerint nem igényel. A T-sejtes immunválasz sérülése esetén ugyanakkor a korábban latens fertőzés reaktiválódik, esetenként súlyos szervi érintettséggel járó vírusbetegség alakulhat ki. A jelenleg elérhető humán cytomegalovirusellenes vegyületek száma csekély, megelőzés, illetve kezelés céljából ganciklovir, valganciklovir, foszkarnet vagy cidofovir adható. A felsorolt szerek klinikai használatát legfőképpen a toxicitásuk korlátozza. Új terápiás alternatívák után kutatva egyedül a terminázkomplex-gátló letermovir hatékonyságát és tolerálhatóságát sikerült bizonyítani. Őssejttranszplantáltak körében végzett klinikai vizsgálatban a letermovir szignifikánsan csökkentette a humán cytomegalovirusreaktiváció arányát, javította a túlélést. Az alkalmazhatóságot korlátozó mellékhatást nem észleltek. A humán cytomegalovirusreaktiváció szempontjából veszélyeztetett betegek körében megfelelő antivirális stratégiát kell követni. A legelőnyösebbnek az antivirális profilaxis, illetve a diagnosztika által vezérelt preemptív terápia tűnik. Orv Hetil. 2019; 160(10): 363–369.

  • 1

    Sinkó J. Current treatment modalities of immunocompromised patients with cytomegalovirus infection. I. Epidemiological and clinical perspectives. [Aktualitások a sérült immunitású betegek cytomegalovirusinfekcióinak ellátásában. I. Epidemiológia és klinikai szempontok.] Orv Hetil. 2019; 160: 83–92. [Hungarian]

  • 2

    Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–753.

  • 3

    Prentice HG, Gluckman E, Powles RL, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant. 1997; 19: 129–133.

  • 4

    Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050–3056.

  • 5

    Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999; 340: 1462–1470.

  • 6

    Nakamura R, Cortez K, Solomon S, et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 30: 235–242.

  • 7

    Ruiz-Camps I, Len O, de la Cámara R, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Antivir Ther. 2011; 16: 951–957.

  • 8

    Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009; 9: 1205–1213.

  • 9

    Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013; 2: CD003774.

  • 10

    Montesinos P, Sanz J, Cantero S, et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009; 15: 730–740.

  • 11

    Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

  • 12

    Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34: 115–121.

  • 13

    Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015; 162: 1–10.

  • 14

    Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis. 2015; 28: 293–299.

  • 15

    Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.

  • 16

    Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989; 9: 316–321.

  • 17

    7th European Conference on Infections in Leukemia. 21–23 Sep, 2017. Sophia Antipolis, France. http://www.ecil-leukaemia.com/ [accessed: September 22, 2018].

  • 18

    Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388–392.

  • 19

    de la Cámara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016; 8: e2016031.

  • 20

    Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013; 369: 1227–1236.

  • 21

    Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial. Biol Blood Marrow Transplant. 2016; 22: S23.

  • 22

    Marty FM, Ljungman P, Papanicolaou GA, et al., Maribavir 1263–300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011; 11: 284–292.

  • 23

    Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012; 12: 3021–3030.

  • 24

    Chemaly RF, Ullmann AJ, Stoelben S, et al., AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370: 1781–1789.

  • 25

    Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017; 377: 2433–2444.

  • 26

    Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018; 2: 2159–2175.

  • 27

    Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res. 2018; 159: 153–174.

  • 28

    Emery V, Zuckerman M, Jackson G, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013; 162: 25–39.

  • 29

    Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333–360.

  • 30

    Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs 2018; 78: 1085–1103.

  • 31

    Kállay K, Kassa Cs, Réti M, et al. Early experience with CliniMACS Prodigy CCS (IFN-gamma) System in selection of virus-specific T-cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation. J Immunother. 2018; 41: 158–163.

  • 32

    Martín-Gandul C, Pérez-Romero P, Sánchez M, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013; 56: 13–18.

  • 33

    Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018; 24: 806–814.

  • 34

    Varga M, Remport Á, Hídvégi M, et al. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience. Transpl Infect Dis. 2005; 7: 63–67.

  • 35

    Irsai G, Tampu-Kiss T, Dezső B, et al. Complications of systemic cytomegalovirus infection in therapy refracter Hodgkin’s lymphoma. [Szisztémás cytomegalovirus-fertőzés és szövődményei terápiarefrakter klasszikus Hodgkin-lymphomában.] Orv Hetil. 2012; 153: 751–755. [Hungarian]

  • 36

    Kullmann T, Kárász T, Gartner B, et al. Acute cytomegalovirus infection-associated hemophagocytic syndrome in a patient treated with azathioprine. [Azathioprin adása mellett kialakult haemophagocytosis szindrómával szövődött akut cytomegalovirus-fertőzés.] Orv Hetil. 2013; 154: 1959–1961. [Hungarian]